Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triple Intralesional Antigen Immunotherapy for Recalcitrant Warts
NCT05254561Phase 3Completed
- Sponsor
- Zagazig University
- Start
- Nov 2020
- Primary completion
- Jun 2021
- Modality
- Recombinant Proteins and Enzymes, Live Attenuated Vaccines
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tuberculin purified protein derivative, candida albicans antigen and M-M-R II in warts (4 arms), sponsored by Zagazig University. Primary endpoints: Overall complete response of both treated and distant warts at 12 weeks and Immediate adverse effects at 20 minutes. Started Nov 2020; status: completed.
02
Drugs
tuberculin purified protein derivativecandida albicans antigenM-M-R II
03
Conditions
warts
Beyond the preview
Go deeper on NCT05254561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05254561.